Form 4 for MYGN MYRIAD GENETICS INC
Accepted 2026-03-16 00:00:00 ET · period of report 2026-03-12 · accession 0002065630-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | 2026-03-12 | MYGN | Donnelly Brian J | Chief Commerical Off | A - Grant | $0.00 | +226.8K | 624.3K | +57% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-12 | A | A | 226,804 | $0.00 | 624,338 | D | — | — | (F1) Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. |